Metabolic Liver Disease Projected to Affect 1.8 Billion People Worldwide by 2050
A groundbreaking study published in the Lancet Gastroenterology & Hepatology journal has issued a stark warning: metabolic dysfunction-associated steatotic liver disease (MASLD) is set to impact a staggering 1.8 billion individuals globally by 2050. This represents a 42% increase from the current estimate of 1.3 billion people living with the condition, highlighting a rapid and concerning escalation in prevalence.
Rising Prevalence and Demographic Trends
The research, part of the global burden of diseases, injuries, and risk factors study (GBD), indicates that MASLD—formerly known as non-alcoholic fatty liver disease (NAFLD)—now affects approximately one in six people worldwide, or 16% of the global population. This marks a dramatic 143% surge since 1990, when only 500 million cases were recorded. The global prevalence rate has climbed to 14,429 cases per 100,000 people in 2023, a 29% rise over the past three decades.
While MASLD is more common in men than women and peaks in older adults aged 80 to 84, the largest affected groups are younger individuals. Specifically, men around 35 to 39 years old and women aged 55 to 59 bear the highest burden, underscoring a shift towards earlier onset linked to modern lifestyles.
Key Drivers and Regional Variations
The study identifies high blood sugar as the primary driver of MASLD-related health issues globally, followed closely by high body mass index (BMI) and smoking. This underscores strong connections to type 2 diabetes and obesity, which are fuelling the disease's spread. Certain regions, such as north Africa and the Middle East, exhibit disproportionately high rates of MASLD, but sharp increases have been observed worldwide.
In the United Kingdom, prevalence rates jumped by 33% between 1990 and 2023, the highest rise in western Europe. Similarly, Australia saw a 30% increase, and the United States experienced a 22% uptick, reflecting a broad global trend.
Health Impacts and Future Risks
Despite the growing number of cases, the overall health impact—measured in years lost due to illness or death—has remained stable. This suggests that advancements in treatment and care are enabling people to live longer and healthier lives, with many new cases detected in early stages. However, the sheer volume of individuals affected means that millions remain at risk of developing severe complications, including liver cirrhosis or cancer in the future.
MASLD is often associated with being overweight and can typically be managed through lifestyle modifications, such as improved diet and increased physical activity. The condition frequently presents without symptoms, leading many to be unaware of their diagnosis until it is incidentally discovered during tests for other health issues. Potential symptoms may include fatigue, general malaise, and abdominal discomfort under the right side of the ribs.
Call to Action and Research Insights
Conducted by the Institute for Health Metrics and Evaluation at the University of Washington in Seattle, the study emphasises that MASLD is increasingly impacting younger adults amid deteriorating health and lifestyle patterns. The authors urge that this condition be recognised as a global health priority, advocating for the development of targeted policies, awareness campaigns, and interventions to mitigate its escalating impact and prevent future complications.
As population growth combines with rising obesity and high blood sugar levels, proactive measures are essential to curb this silent epidemic and safeguard public health for generations to come.
